BBLG Quote, Financials, Valuation and Earnings

INmune Bio has a net margin of -- compared to Bone Biologics's net margin of -19478%. Bone Biologics's return on equity of -- beat INmune Bio's return on equity of -122.48%.

Bone Biologics has a consensus price target of $22.50, signalling upside risk potential of 670.55%. On the other hand INmune Bio has an analysts' consensus of $7.65 which suggests that it could grow by 119.64%. Given that Bone Biologics has higher upside potential than INmune Bio, analysts believe Bone Biologics is more attractive than INmune Bio.

Bone Biologics has a beta of 1.215, which suggesting that the stock is 21.528% more volatile than S&P 500. In comparison INmune Bio has a beta of 1.336, suggesting its more volatile than the S&P 500 by 33.612%.

Bone Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INmune Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bone Biologics pays -- of its earnings as a dividend. INmune Bio pays out -- of its earnings as a dividend.

Bone Biologics quarterly revenues are --, which are smaller than INmune Bio quarterly revenues of $50K. Bone Biologics's net income of -$1M is higher than INmune Bio's net income of -$9.7M. Notably, Bone Biologics's price-to-earnings ratio is -- while INmune Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics is -- versus 1,061.01x for INmune Bio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Bone Biologics's net margin of -49.65%. Bone Biologics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Bone Biologics has a consensus price target of $22.50, signalling upside risk potential of 670.55%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Bone Biologics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Bone Biologics is more attractive than NovaBay Pharmaceuticals.

Bone Biologics has a beta of 1.215, which suggesting that the stock is 21.528% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Bone Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bone Biologics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Bone Biologics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Bone Biologics's net income of -$1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Bone Biologics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Bone Biologics's net margin of --. Bone Biologics's return on equity of -- beat Oragenics's return on equity of --.

Bone Biologics has a consensus price target of $22.50, signalling upside risk potential of 670.55%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1998.11%. Given that Oragenics has higher upside potential than Bone Biologics, analysts believe Oragenics is more attractive than Bone Biologics.

Bone Biologics has a beta of 1.215, which suggesting that the stock is 21.528% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Bone Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bone Biologics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Bone Biologics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Bone Biologics's net income of -$1M is higher than Oragenics's net income of -$2.2M. Notably, Bone Biologics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics is -- versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Bone Biologics's net margin of --. Bone Biologics's return on equity of -- beat Theriva Biologics's return on equity of --.

Bone Biologics has a consensus price target of $22.50, signalling upside risk potential of 670.55%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1367.51%. Given that Theriva Biologics has higher upside potential than Bone Biologics, analysts believe Theriva Biologics is more attractive than Bone Biologics.

Bone Biologics has a beta of 1.215, which suggesting that the stock is 21.528% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Bone Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bone Biologics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Bone Biologics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Bone Biologics's net income of -$1M is higher than Theriva Biologics's net income of -$4.3M. Notably, Bone Biologics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.